{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:06:16Z","timestamp":1772136376090,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74636-6","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T02:02:11Z","timestamp":1727834531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Huancheng","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongzhi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rendong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhemin","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jundong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaochen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"74636_CR1","doi-asserted-by":"crossref","unstructured":"1. Patel SP, Othus M, Chen Y, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023;388(9):813\u2013823.","DOI":"10.1056\/NEJMoa2211437"},{"key":"74636_CR2","doi-asserted-by":"crossref","unstructured":"2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u2013263.","DOI":"10.3322\/caac.21834"},{"key":"74636_CR3","doi-asserted-by":"crossref","unstructured":"3. Berta J, T\u00f6r\u00f6k S, T\u00e1rnoki-Z\u00e1ch J, et al. Apelin promotes blood and lymph vessel formation and the growth of melanoma lung metastasis. Sci Rep. 2021;11(1):5798.","DOI":"10.1038\/s41598-021-85162-0"},{"key":"74636_CR4","doi-asserted-by":"crossref","unstructured":"4. Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018;392(10151):971\u2013984.","DOI":"10.1016\/S0140-6736(18)31559-9"},{"key":"74636_CR5","doi-asserted-by":"crossref","unstructured":"5. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med.\u00a0 2016;375(19):1845\u20131855.","DOI":"10.1056\/NEJMoa1611299"},{"key":"74636_CR6","doi-asserted-by":"crossref","unstructured":"6. Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clin Cancer Res. 2018;24(6):1260\u20131270.","DOI":"10.1158\/1078-0432.CCR-17-2267"},{"key":"74636_CR7","doi-asserted-by":"crossref","unstructured":"7. Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12(1):54.","DOI":"10.1186\/s13045-019-0738-1"},{"key":"74636_CR8","doi-asserted-by":"crossref","unstructured":"8. Wang D, Elenbaas B, Murugesan K, et al. Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays. NPJ Precis Oncol. 2023;7(1):103.","DOI":"10.1038\/s41698-023-00442-4"},{"key":"74636_CR9","doi-asserted-by":"crossref","unstructured":"9. Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Cancers (Basel). 2021;13(3):558.","DOI":"10.3390\/cancers13030558"},{"key":"74636_CR10","unstructured":"10. Grasso CS, Tsoi J, Onyshchenko M, et al. Conserved Interferon-\u03b3 Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020;38(4):500\u2013515.e3."},{"key":"74636_CR11","doi-asserted-by":"crossref","unstructured":"11. Ma D, Zhang Q, Duan Q, et al. Identification of IGF1R mutation as a novel predictor of efficacious immunotherapy in melanoma. J Transl Med. 2022;20(1):172.","DOI":"10.1186\/s12967-022-03324-8"},{"key":"74636_CR12","doi-asserted-by":"crossref","unstructured":"12. Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death [published correction appears in J Immunother Cancer. 2020 May;8(1):]. J Immunother Cancer. 2020;8(1):e000337.","DOI":"10.1136\/jitc-2019-000337corr1"},{"key":"74636_CR13","doi-asserted-by":"crossref","unstructured":"13. Alzeibak R, Mishchenko TA, Shilyagina NY, Balalaeva IV, Vedunova MV, Krysko DV. Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. J Immunother Cancer. 2021;9(1):e001926.","DOI":"10.1136\/jitc-2020-001926"},{"key":"74636_CR14","doi-asserted-by":"crossref","unstructured":"14. Kepp O, Zitvogel L, Kroemer G. Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer. Oncoimmunology. 2020;9(1):1795995. Published 2020 Jul 21.","DOI":"10.1080\/2162402X.2020.1795995"},{"key":"74636_CR15","doi-asserted-by":"crossref","unstructured":"15. Montes de Oca R, Alavi AS, Vitali N, et al. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo. Mol Cancer Ther. 2021;20(10):1941\u20131955.","DOI":"10.1158\/1535-7163.MCT-21-0035"},{"key":"74636_CR16","doi-asserted-by":"crossref","unstructured":"16. Fucikova J, Moserova I, Urbanova L, et al. Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol. 2015;6:402.","DOI":"10.3389\/fimmu.2015.00402"},{"key":"74636_CR17","doi-asserted-by":"crossref","unstructured":"17. Liu J, Kuang F, Kang R, Tang D. Alkaliptosis: a new weapon for cancer therapy. Cancer Gene Ther. 2020;27(5):267\u2013269.","DOI":"10.1038\/s41417-019-0134-6"},{"key":"74636_CR18","doi-asserted-by":"crossref","unstructured":"18. Chen F, Kang R, Liu J, Tang D. Mechanisms of alkaliptosis. Front Cell Dev Biol. 2023;11:1213995.","DOI":"10.3389\/fcell.2023.1213995"},{"key":"74636_CR19","doi-asserted-by":"crossref","unstructured":"19. Xie J, Yang Y, Gao Y, He J. Cuproptosis: mechanisms and links with cancers. Mol Cancer. 2023;22(1):46.","DOI":"10.1186\/s12943-023-01732-y"},{"key":"74636_CR20","doi-asserted-by":"crossref","unstructured":"20. Holze C, Michaudel C, Mackowiak C, et al. Oxeiptosis, a ROS-induced caspase-independent apoptosis-like cell-death pathway. Nat Immunol. 2018;19(2):130\u2013140.","DOI":"10.1038\/s41590-017-0013-y"},{"key":"74636_CR21","doi-asserted-by":"crossref","unstructured":"21. Huang P, Chen G, Jin W, Mao K, Wan H, He Y. Molecular Mechanisms of Parthanatos and Its Role in Diverse Diseases. Int J Mol Sci. 2022;23(13):7292.","DOI":"10.3390\/ijms23137292"},{"key":"74636_CR22","doi-asserted-by":"crossref","unstructured":"22. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30(1):87.","DOI":"10.1186\/1756-9966-30-87"},{"key":"74636_CR23","doi-asserted-by":"crossref","unstructured":"23. Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395\u2013417.","DOI":"10.1038\/s41571-020-0341-y"},{"key":"74636_CR24","doi-asserted-by":"crossref","unstructured":"24. Meier P, Legrand AJ, Adam D, Silke J. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat Rev Cancer. 2024;24(5):299\u2013315.","DOI":"10.1038\/s41568-024-00674-x"},{"key":"74636_CR25","doi-asserted-by":"crossref","unstructured":"25. Kianfar M, Balcerak A, Chmielarczyk M, Tarnowski L, Grzybowska EA. Cell Death by Entosis: Triggers, Molecular Mechanisms and Clinical Significance. Int J Mol Sci. 2022;23(9):4985.","DOI":"10.3390\/ijms23094985"},{"key":"74636_CR26","doi-asserted-by":"crossref","unstructured":"26. Berg AL, Rowson-Hodel A, Wheeler MR, Hu M, Free SR, Carraway KL III. Engaging the Lysosome and Lysosome-Dependent Cell Death in Cancer. In: Mayrovitz HN, ed. Breast Cancer. Brisbane (AU): Exon Publications; August 6, 2022.","DOI":"10.36255\/exon-publications-breast-cancer-lysosome"},{"key":"74636_CR27","doi-asserted-by":"crossref","unstructured":"27. Riaz N, Havel JJ, Makarov V, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017;171(4):934\u2013949.e16.","DOI":"10.1016\/j.cell.2017.09.028"},{"key":"74636_CR28","doi-asserted-by":"crossref","unstructured":"28. Gide TN, Quek C, Menzies AM, et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1\/Anti-CTLA-4 Combined Therapy. Cancer Cell. 2019;35(2):238\u2013255.e6.","DOI":"10.1016\/j.ccell.2019.01.003"},{"key":"74636_CR29","doi-asserted-by":"crossref","unstructured":"29. Abril-Rodriguez G, Torrejon DY, Liu W, et al. PAK4 inhibition improves PD-1 blockade immunotherapy [published correction appears in Nat Cancer. 2020 Feb;1(2):264]. Nat Cancer. 2020;1(1):46\u201358.","DOI":"10.1038\/s43018-020-0025-7"},{"key":"74636_CR30","doi-asserted-by":"crossref","unstructured":"30. YOUDEN WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u201335. doi:10.1002\/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3"},{"key":"74636_CR31","doi-asserted-by":"crossref","unstructured":"31. Xie X, Li X, Yao W. A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors. Transl Cancer Res. 2021;10(2):1119\u20131130.","DOI":"10.21037\/tcr-20-2547"},{"key":"74636_CR32","doi-asserted-by":"crossref","unstructured":"32. Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20131558.","DOI":"10.1038\/s41591-018-0136-1"},{"key":"74636_CR33","doi-asserted-by":"crossref","unstructured":"33. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559\u2013572.","DOI":"10.1038\/nri.2017.49"},{"key":"74636_CR34","doi-asserted-by":"crossref","unstructured":"34. Yang S, Wu Y, Deng Y, et al. Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors. Oncoimmunology. 2019;8(12):e1659094.","DOI":"10.1080\/2162402X.2019.1659094"},{"key":"74636_CR35","doi-asserted-by":"crossref","unstructured":"35. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u20132940.","DOI":"10.1172\/JCI91190"},{"key":"74636_CR36","doi-asserted-by":"crossref","unstructured":"36. Auslander N, Zhang G, Lee JS, et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma [published correction appears in Nat Med. 2018 Dec;24(12):1942. doi: 10.1038\/s41591-018-0247-8]. Nat Med. 2018;24(10):1545\u20131549.","DOI":"10.1038\/s41591-018-0157-9"},{"key":"74636_CR37","doi-asserted-by":"crossref","unstructured":"37. Friedlander P, Wassmann K, Christenfeld AM, et al. Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. J Immunother Cancer. 2017;5(1):67.","DOI":"10.1186\/s40425-017-0272-z"},{"key":"74636_CR38","doi-asserted-by":"crossref","unstructured":"38. Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma [published correction appears in Cell. 2017 Jan 26;168(3):542. doi: 10.1016\/j.cell.2017.01.010]. Cell. 2016;165(1):35\u201344.","DOI":"10.1016\/j.cell.2017.01.010"},{"key":"74636_CR39","doi-asserted-by":"crossref","unstructured":"39. Shukla SA, Bachireddy P, Schilling B, et al. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018;173(3):624\u2013633.e8.","DOI":"10.1016\/j.cell.2018.03.026"},{"key":"74636_CR40","doi-asserted-by":"crossref","unstructured":"40. Thompson JC, Hwang WT, Davis C, et al. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer. 2020;139:1\u20138.","DOI":"10.1016\/j.lungcan.2019.10.012"},{"key":"74636_CR41","doi-asserted-by":"crossref","unstructured":"41. Dominguez CX, M\u00fcller S, Keerthivasan S, et al. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15\u2009+\u2009Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discov. 2020;10(2):232\u2013253.","DOI":"10.1158\/2159-8290.CD-19-0644"},{"key":"74636_CR42","doi-asserted-by":"crossref","unstructured":"42. Sooi K, Walsh R, Kumarakulasinghe N, Wong A, Ngoi N. A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer. Cancer Drug Resist. 2023;6(3):656\u2013673.","DOI":"10.20517\/cdr.2023.48"},{"key":"74636_CR43","doi-asserted-by":"crossref","unstructured":"43. Fujiwara Y, Mittra A, Naqash AR, Takebe N. A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. Cancer Drug Resist. 2020;3(3):252\u2013275.","DOI":"10.20517\/cdr.2020.11"},{"key":"74636_CR44","doi-asserted-by":"crossref","unstructured":"44. Chen S, Zhang L, Lin H, Liang Y, Wang Y. Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma. Biomolecules. 2022;13(1):58.","DOI":"10.3390\/biom13010058"},{"key":"74636_CR45","doi-asserted-by":"crossref","unstructured":"45. Chen S, Zhang L, Huang M, Liang Y, Wang Y. A tumor-associated endothelial signature score model in immunotherapy and prognosis across pan-cancers. Front Pharmacol. 2023;14:1190660.","DOI":"10.3389\/fphar.2023.1190660"},{"key":"74636_CR46","doi-asserted-by":"crossref","unstructured":"46. Chen S, Zhang L, Chen L, Huang Q, Wang Y, Liang Y. Comprehensive analysis of glycoprotein VI-mediated platelet activation signaling pathway for predicting pan-cancer survival and response to anti-PD-1 immunotherapy. Comput Struct Biotechnol J. 2023;21:2873\u20132883.","DOI":"10.1016\/j.csbj.2023.04.002"},{"key":"74636_CR47","doi-asserted-by":"crossref","unstructured":"47. Chen S, Huang M, Zhang L, Huang Q, Wang Y, Liang Y. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis. Comput Struct Biotechnol J. 2023;23:369\u2013383.","DOI":"10.1016\/j.csbj.2023.12.001"},{"key":"74636_CR48","doi-asserted-by":"crossref","unstructured":"48. Du K, Wei S, Wei Z, et al. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nat Commun. 2021;12(1):6023.","DOI":"10.1038\/s41467-021-26299-4"},{"key":"74636_CR49","doi-asserted-by":"crossref","unstructured":"49. Demaria O, Cornen S, Da\u00ebron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45\u201356.","DOI":"10.1038\/s41586-019-1593-5"},{"key":"74636_CR50","doi-asserted-by":"crossref","unstructured":"50. Ding D, Jiang X. Advances in Immunogenic Cell Death for Cancer Immunotherapy. Small Methods. 2023;7(5):e2300354.","DOI":"10.1002\/smtd.202300354"},{"key":"74636_CR51","doi-asserted-by":"crossref","unstructured":"51. Kang X, Zhang Y, Song J, et al. A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy. Nat Commun. 2023;14(1):5216.","DOI":"10.1038\/s41467-023-40996-2"},{"key":"74636_CR52","doi-asserted-by":"crossref","unstructured":"52. Wang X, Wu S, Liu F, et al. An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma. Front Immunol. 2021;12:781466.","DOI":"10.3389\/fimmu.2021.781466"},{"key":"74636_CR53","doi-asserted-by":"crossref","unstructured":"53. Liu Z, Sun L, Peng X, Liu S, Zhu Z, Huang C. An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma. Apoptosis. 2023;28(11\u201312):1564\u20131583.","DOI":"10.1007\/s10495-023-01879-5"},{"key":"74636_CR54","doi-asserted-by":"crossref","unstructured":"54. Xu G, Jiang Y, Li Y, et al. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023;149(18):16261\u201316277.","DOI":"10.1007\/s00432-023-05370-1"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74636-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74636-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74636-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T02:04:05Z","timestamp":1727834645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74636-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74636"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74636-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4750701\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study does not involve animal or clinical experiments. All data were obtained from public databases, and therefore, it does not require submission for ethical review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"22872"}}